Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metvix PDT followed by Mohs surgery versus Mohs surgery alone for basal cell carcinoma
2005-004262-16Phase 4Terminated
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Start
- Jan 2006
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methyl aminolevulinate in basal cell carcinoma (BCC) (2 arms), sponsored by Guy's and St Thomas' NHS Foundation Trust. Primary endpoint: Post-Mohs wound defect surface area. Started Jan 2006; status: terminated.
02
Drugs
methyl aminolevulinate
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2005-004262-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004262-16.